Normal ovarian tissue is rich in cytokines. Cytokines and chemokines are important in the physiology of ovarian function and of ovulation. Cytokines and chemokines may recruit cytokine-producing lymphocytes to the site of a developing follicle, and cytokines appear to play an important role in pre and post follicle development. Most of the same cytokines that are found in normal ovarian tissue are also found in association with malignancy in contrast to their functions in normal tissues. It is reasonable to assume that the functions of cytokines associated with malignancy may serve to promote the unregulated growth if tumor cells and metastasis. It is also likely that cytokines produced by tumors will modulate immune responses that favor tumor progression. In the following review, we have highlighted those functions of cytokines that have been identified as having the most significant impact on tumor growth and development. By examining activities of these cytokines in normal and in malignant ovarian tissues, it is hoped that future possible avenues for investigation may be opened up and that the results of these investigations will lead to strategies that can modulate the production or the activity of the cytokines leading to the growth of tumors or their metastases. Such strategies now fall under the general discipline of bioimmunotherapy. This is an expanding discipline as more is learned about growth regulation in cancer, and with the availability and rapid development of new molecules for therapeutic approaches.

This article has been cited by other articles:

				C. N. Landen Jr, M. J. Birrer, and A. K. Sood Early Events in the Pathogenesis of Epithelial Ovarian Cancer J. Clin. Oncol., February 20, 2008; 26(6): 995 - 1005. [Abstract] [Full Text] [PDF]

				B. Lutton and I. Callard Evolution of reproductive-immune interactions Integr. Comp. Biol., December 1, 2006; 46(6): 1060 - 1071. [Abstract] [Full Text] [PDF]

				I. O. Gordon and R. S. Freedman Defective Antitumor Function of Monocyte-Derived Macrophages from Epithelial Ovarian Cancer Patients Clin. Cancer Res., March 1, 2006; 12(5): 1515 - 1524. [Abstract] [Full Text] [PDF]

				W. J. Murdoch Carcinogenic Potential of Ovulatory Genotoxicity Biol Reprod, October 1, 2005; 73(4): 586 - 590. [Abstract] [Full Text] [PDF]

				A. Maccio, C. Madeddu, D. Massa, M. C. Mudu, M. R. Lusso, G. Gramignano, R. Serpe, G. B. Melis, and G. Mantovani Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia Blood, July 1, 2005; 106(1): 362 - 367. [Abstract] [Full Text] [PDF]

				E. Gorelik, D. P. Landsittel, A. M. Marrangoni, F. Modugno, L. Velikokhatnaya, M. T. Winans, W. L. Bigbee, R. B. Herberman, and A. E. Lokshin Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 981 - 987. [Abstract] [Full Text] [PDF]

				E. Wang, Y. Ngalame, M. C. Panelli, H. Nguyen-Jackson, M. Deavers, P. Mueller, W. Hu, C. A. Savary, R. Kobayashi, R. S. Freedman, et al. Peritoneal and Subperitoneal Stroma May Facilitate Regional Spread of Ovarian Cancer Clin. Cancer Res., January 1, 2005; 11(1): 113 - 122. [Abstract] [Full Text] [PDF]

				E. Efimova, O. Martinez, A. Lokshin, T. Arima, and B. S. Prabhakar IG20, a MADD Splice Variant, Increases Cell Susceptibility to {gamma}-Irradiation and Induces Soluble Mediators That Suppress Tumor Cell Growth Cancer Res., December 15, 2003; 63(24): 8768 - 8776. [Abstract] [Full Text] [PDF]

				A. A. Arslan, A. Zeleniuch-Jacquotte, E. Lundin, A. Micheli, A. Lukanova, Y. Afanasyeva, P. Lenner, V. Krogh, P. Muti, S. Rinaldi, et al. Serum Follicle-Stimulating Hormone and Risk of Epithelial Ovarian Cancer in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1531 - 1535. [Abstract] [Full Text] [PDF]

				N. L.G. Sieben, S. M. Kolkman-Uljee, A. M. Flanagan, S. le Cessie, A.-M. Cleton-Jansen, C. J. Cornelisse, and G. J. Fleuren Molecular Genetic Evidence for Monoclonal Origin of Bilateral Ovarian Serous Borderline Tumors Am. J. Pathol., April 1, 2003; 162(4): 1095 - 1101. [Abstract] [Full Text] [PDF]

				Y.-P. Han, Y.-D. Nien, and W. L. Garner Tumor Necrosis Factor-alpha -induced Proteolytic Activation of Pro-matrix Metalloproteinase-9 by Human Skin Is Controlled by Down-regulating Tissue Inhibitor of Metalloproteinase-1 and Mediated by Tissue-associated Chymotrypsin-like Proteinase J. Biol. Chem., July 19, 2002; 277(30): 27319 - 27327. [Abstract] [Full Text] [PDF]

				M. A. Nash, A. E. Loercher, and R. S. Freedman In Vitro Growth Inhibition of Ovarian Cancer Cells by Decorin: Synergism of Action between Decorin and Carboplatin Cancer Res., December 1, 1999; 59(24): 6192 - 6196. [Abstract] [Full Text] [PDF]